Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • emc易倍官网入口Media Updates
    • Media Resources
    • emc易倍官网入口Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • emc易倍官网入口Shareholder Information
    • Subscribe
    • emc易倍官网入口Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • emc易倍官网入口Careers
    • Working at Ipsen
    • emc易倍官网入口Culture
    • emc易倍官网入口Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • emc易倍官网入口Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • emc易倍官网入口Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • Brazil
    • Canada
    • United States
    • Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • emc易倍官网入口 Japan
    • emc易倍官网入口 Belgium
    • Ukraine
    • emc易倍官网入口 UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • emc易倍官网入口 Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • emc易倍官网入口Company
    • emc易倍官网入口Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • emc易倍官网入口Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • emc易倍官网入口Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • emc易倍官网入口Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • emc易倍官网入口Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories

emc易倍官网入口

Previous
Next

emc易倍官网入口

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-08-14-Ipsen-Voting-rights

emc易倍官网入口

- 12 January 2021 - 1 mins read

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • emc易倍官网入口2026-08-14-Ipsen-Voting-rights

emc易倍官网入口

Previous
Next
Related stories
01 June 2021 1 mins read

Ipsen announces the launch of an Employee Shareholding Plan
emc易倍官网入口 See more stories

emc易倍官网入口

11 July 2024

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for...
09 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
09 July 2024

Ipsen – June 2024 – Monthly information relative to the...
08 July 2024

Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
02 July 2024

Ipsen expands collaboration and license agreement for development of Cabometyx?...
25 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
18 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
11 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
10 June 2024

Ipsen’s Iqirvo? receives U.S. FDA accelerated approval as a first-in-class...

IPN price

€157.50

 €2.00 (1.29%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-14 3:39:39